YK Bioventures Opportunities GP I, LLC

CIK: 0002042634

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (100.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CERO

CERO THERAPEUTICS HOLDINGS, INC.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (7 total)

CERO
CERO THERAPEUTICS HOLDINGS, INC.
Dec 13, 2024
Sale(S)
Indirect
3M shares at avg. $0.06$180K
CERO
CERO THERAPEUTICS HOLDINGS, INC.
Dec 12, 2024
Sale(S)
Indirect
1.6M shares at avg. $0.07$113K
CERO
CERO THERAPEUTICS HOLDINGS, INC.
Dec 11, 2024
Sale(S)
Indirect
1.3M shares at avg. $0.08$108K
CERO
CERO THERAPEUTICS HOLDINGS, INC.
Dec 10, 2024
Sale(S)
Indirect
1.6M shares at avg. $0.09$141K
CERO
CERO THERAPEUTICS HOLDINGS, INC.
Dec 9, 2024
Sale(S)
Indirect
850.5K shares at avg. $0.11$94K
CERO
CERO THERAPEUTICS HOLDINGS, INC.
Dec 6, 2024
Sale(S)
Indirect
1.2M shares at avg. $0.12$148K
CERO
CERO THERAPEUTICS HOLDINGS, INC.
Oct 10, 2024
Sale(S)
Indirect
3.3M shares at avg. $0.10$325K

		Type	Shares	Price		Ownership
Dec 13, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	2,998,908	$0.06	$179,934	Indirect
Dec 12, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	1,614,541	$0.07	$113,018	Indirect
Dec 11, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	1,343,801	$0.08	$107,504	Indirect
Dec 10, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	1,570,947	$0.09	$141,385	Indirect
Dec 9, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	850,543	$0.11	$93,560	Indirect
Dec 6, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	1,236,874	$0.12	$148,425	Indirect
Oct 10, 2024	CERO CERO THERAPEUTICS HOLDINGS, INC.	Sale(S)	3,250,000	$0.10	$325,000	Indirect

1-7 of 7 transactions

About YK Bioventures Opportunities GP I, LLC

YK Bioventures Opportunities GP I, LLC (SEC CIK 0002042634) files insider reports with the SEC as 10% Owner of CERO THERAPEUTICS HOLDINGS, INC. (CERO).

Signal8 holds 4 ownership filings by YK Bioventures Opportunities GP I, LLC (1 Form 3, 3 Form 4), filed between Nov 14, 2024 and Dec 13, 2024. Those filings report 7 transactions, from Oct 10, 2024 to Dec 13, 2024. Signal8's Form 4 history starts in Sep 2024.

The business address on YK Bioventures Opportunities GP I, LLC's filings is in BURLINGAME, CA.

Recent filings by YK Bioventures Opportunities GP I, LLC

Dec 13, 2024: Open-market sale of CERO shares (Form 4, code S).
Dec 12, 2024: Open-market sale of CERO shares (Form 4, code S).
Dec 11, 2024: Open-market sale of CERO shares (Form 4, code S).
Dec 10, 2024: Open-market sale of CERO shares (Form 4, code S).
Dec 9, 2024: Open-market sale of CERO shares (Form 4, code S).

Other insiders filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Francois Eric, Director
Rolfe Lindsey, Director
LAPORTE KATHLEEN, Director
Pierce Kristen, Chief Development Officer
Patel Shami, Director
ATWOOD BRIAN G, Director

How to read Form 4 transaction codes